MedGenesis said GDNF has already showed disease-modifying potential in treating parkinson’s disease and now will be evaluated for epilepsy.
SynapCell will provide a detailed review of the effects of GDNF on the frequency and intensity of behavioral and electroencephalographic seizures in the final report.
SynapCell CEO Corinne Roucard said this project falls within the scope of the company’s core business: assessing the efficacy of epilepsy treatments.
"We are now moving ahead with the actual research, which will go on for nine months," Roucard said .